Company profile
Alexion Pharmaceuticals, Inc. (subsidiary of AstraZeneca)
Subsidiary of AstraZeneca (AZN)
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Eculizumab(Soliris) | Phase 3 | Complement C5Monoclonal antibody | HypertensionChronic Kidney Disease |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.